BDX:NYE-Becton, Dickinson and Company (USD)

COMMON STOCK | Medical Instruments & Supplies | NYE

Last Closing Price

USD 224.08

Change

0.00 (0.00)%

Market Cap

USD 64.95B

Volume

1.38M

Average Target Price

USD 273.25 (+21.94%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. It has a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey. Address: 1 Becton Drive, Franklin Lakes, NJ, United States, 07417

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BAX Baxter International Inc

N/A

USD40.32B 43.97 22.94
ALC Alcon Inc

N/A

USD27.52B N/A 35.48
RMD ResMed Inc

N/A

USD24.49B 39.38 26.39
WST West Pharmaceutical Services, ..

N/A

USD19.90B 73.10 45.93
COO The Cooper Companies, Inc

N/A

USD17.78B 58.86 31.23
VAR Varian Medical Systems, Inc

N/A

USD15.68B 59.67 32.02
TFX Teleflex Incorporated

N/A

USD15.62B 32.43 26.45
STE STERIS plc

N/A

USD14.48B 35.73 20.87
HRC Hill-Rom Holdings, Inc

N/A

USD5.47B 26.68 13.27
HAE Haemonetics Corporation

N/A

USD4.42B 44.89 19.34

ETFs Containing BDX

Symbol Name Weight Mer Price(Change) Market Cap
BSCO Invesco BulletShares 2024.. 0.00 % 0.10 %

N/A

USD1.09B
IBDK iShares iBonds Dec 2019 T.. 0.00 % 0.10 %

N/A

USD0.63B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

USD6.60B
PFF iShares Preferred and Inc.. 0.00 % 0.46 %

N/A

USD15.21B
PFXF VanEck Vectors Preferred .. 0.00 % 0.41 %

N/A

USD0.68B
VSL Volshares Large Cap ETF 0.00 % 0.65 %

N/A

USD3.08M
WOMN:CA BMO Women In Leadership F.. 0.00 % 0.39 %

N/A

USD0.06B
FHI Federated Hermes, Inc 0.00 % 0.00 %

N/A

N/A
FHI:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

USD0.20B
FHI-B:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.61% 35% F 37% F
Dividend Return 0.87% 100% A+ 26% F
Total Return -16.74% 35% F 36% F
Trailing 12 Months  
Capital Gain -9.66% 35% F 44% F
Dividend Return 1.27% 100% A+ 29% F
Total Return -8.38% 35% F 41% F
Trailing 5 Years  
Capital Gain 71.20% 17% F 82% B-
Dividend Return 11.31% 88% B+ 34% F
Total Return 82.50% 17% F 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 13.28% N/A N/A 84% B
Dividend Return 1.50% N/A N/A 44% F
Total Return 14.78% N/A N/A 84% B
Risk Return Profile  
Volatility (Standard Deviation) 11.47% N/A N/A 66% D
Risk Adjusted Return 128.89% N/A N/A 96% A
Market Capitalization 64.95B 100% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 78.15 22% F 8% F
Price/Book Ratio 2.67 80% B- 28% F
Price / Cash Flow Ratio 19.51 55% F 16% F
EV/EBITDA 22.58 63% D 19% F
Management Effectiveness  
Return on Equity 3.99% 45% F 47% F
Return on Invested Capital 4.32% 35% F 43% F
Return on Assets 2.84% 40% F 61% D-
Debt to Equity Ratio 85.77% 33% F 40% F
Technical Ratios  
Short Ratio 1.85 90% A- 55% F
Short Percent 1.14% 89% B+ 82% B-
Beta 0.86 63% D 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector